➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
McKesson
Mallinckrodt
Merck
McKinsey

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

Teva Pharms Usa Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for TEVA PHARMS USA, and what generic and branded alternatives to TEVA PHARMS USA drugs are available?

TEVA PHARMS USA has one hundred and sixty-five approved drugs.

There are twenty-three tentative approvals on TEVA PHARMS USA drugs.

Summary for Teva Pharms Usa
US Patents:0
Tradenames:144
Ingredients:141
NDAs:165

Drugs and US Patents for Teva Pharms Usa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa SELFEMRA fluoxetine hydrochloride TABLET;ORAL 200151-001 Feb 3, 2014 DISCN No No   Start Trial   Start Trial
Teva Pharms Usa MYCOPHENOLIC ACID mycophenolic acid TABLET, DELAYED RELEASE;ORAL 202720-001 Oct 30, 2014 DISCN No No   Start Trial   Start Trial
Teva Pharms Usa DEXMETHYLPHENIDATE HYDROCHLORIDE dexmethylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 202731-003 May 19, 2014 AB RX No No   Start Trial   Start Trial
Teva Pharms Usa CISPLATIN cisplatin INJECTABLE;INJECTION 074814-001 May 16, 2000 DISCN No No   Start Trial   Start Trial
Teva Pharms Usa ESCITALOPRAM OXALATE escitalopram oxalate TABLET;ORAL 076765-001 Mar 14, 2012 AB RX No No   Start Trial   Start Trial
Teva Pharms Usa OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 200532-001 Apr 24, 2017 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Teva Pharms Usa

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 7,199,098   Start Trial
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 6,620,847   Start Trial
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 6,939,539   Start Trial
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 5,981,589   Start Trial
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 6,054,430   Start Trial
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 6,939,539   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for TEVA PHARMS USA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-01-29
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-02-26
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Harvard Business School
Colorcon
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.